Lyrica
Product Images NDC 71610-071

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 71610-071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0071 30)

Label of Lyrica (Pregabalin) capsules, 25 mg strength, with a quantity of 30 capsules. The label includes a warning that the medication may be habit forming, storage instructions, and manufacturing information indicating it is made by Pfizer Asia Pacific Pte. Ltd. in Singapore and repackaged by Aphena Pharma Solutions - Tennessee, LLC. The label also shows the product NDC 71610-0071 and states RX Only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Cockcroft And Gault Equation (Lyrica 01)

A mathematical formula showing the calculation of Creatinine Clearance (CLCr) adjusted for age, weight, and serum creatinine, including a factor of 0.85 for female patients. The variables are arranged in a fraction involving age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram of the active ingredient in Lyrica, showing the molecular arrangement including a carboxyl group (CO2H) and an amino group (NH2) attached to a chiral carbon.*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares Pregabalin 200 mg, 100 mg, and 25 mg taken three times a day against a placebo, showing different response rates in patient improvement.*

FDA Label Image

Figure 2 (Lyrica 04)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved, showing two curves labeled 'Pregabalin 100 mg three times a day' and 'Placebo.' The vertical axis ranges from 0 to 100 percent of patients improved, and the horizontal axis shows percent improvement from 0 to 100. Two vertical lines are present around the 30 and 50 percent improvement marks.*

FDA Label Image

Figure 3 (Lyrica 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, showing comparative patient improvement across varying pain reduction percentages.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph showing percent of patients improved versus percent improvement in pain from baseline, comparing pregabalin 200 mg three times a day, pregabalin 100 mg three times a day, and placebo groups. The graph illustrates differences in patient improvement across these treatment groups.*

FDA Label Image

Figure 5 (Lyrica 07)

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The chart uses different line styles to distinguish treatments and shows patient improvement trends over increasing pain reduction percentages.*

FDA Label Image

Figure 6 (Lyrica 08)

A bar graph comparing responder rates (%) across dosing groups in two studies labeled E1 and E3. The x-axis shows dosages including placebo, 50 mg, 150 mg, 300 mg, and 600 mg daily, with participant numbers listed below. The y-axis measures responder rate from 0% to 60%. The graph highlights a trend of increasing responder rates with higher doses.*

FDA Label Image

Figure 7 (Lyrica 09)

A line graph depicting median percent reduction in seizure change from baseline versus dose in mg/day for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. The graph shows increasing seizure reduction with higher doses, with significant p-values indicated at various dose points.*

FDA Label Image

Figure 8 (Lyrica 10)

A bar chart comparing responder rates in percentage for three groups: Placebo (22.6% with 93 subjects), 2.5 mg/kg/day dose (29.1% with 103 subjects), and 10 mg/kg/day dose (40.6% with 96 subjects). The y-axis represents responder rate percentages from 0 to 60%. *

FDA Label Image

Figure 9 (Lyrica 11)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at 300 mg, 450 mg, and 600 mg daily doses compared to placebo. The graph shows four curves illustrating the efficacy distribution of each dosing group over a range of pain improvement percentages.*

FDA Label Image

Figure 10 (Lyrica 12)

A Kaplan-Meier survival plot depicting the estimated percentage of subjects without LTR over 180 days, comparing Pregabalin and Placebo groups. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis shows the days from 0 to 180. The solid line indicates Pregabalin, and the dashed line indicates Placebo, with Pregabalin showing higher percentages without LTR.*

FDA Label Image

Figure 11 (Lyrica 13)

A line chart depicting the percent of subjects improved over a range of percentage improvements from baseline to Week 12 using the BOCF method. The chart compares two groups: Pregabalin, represented by a solid line, and Placebo, represented by a dotted line, showing a higher percentage of subjects improved with Pregabalin across the range.*

FDA Label Image

Figure 12 (Lyrica 14)

A line graph comparing the percent of subjects improved over baseline to week 16 BOCF between Pregabalin and placebo groups. The x-axis shows percent improvement from >0 to 100, and the y-axis shows the percent of subjects improved from 0% to 100%. The solid line represents Pregabalin, and the dashed line represents placebo.*

FDA Label Image

Logo (Lyrica 14a)

FDA Label Image

Logo (Lyrica 14b)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.